HealthyPhase 1PDRNCT06796361
Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness
A Phase 1 study testing Ketanserin 40mg plus Psilocybin 40mg, 40mg Psilocybin and 20mg Psilocybin in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Read more about this study
- Who is it for?
- Ages 25 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Ketanserin 40mg plus Psilocybin 40mg, 40mg Psilocybin and 20mg Psilocybin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteSwitzerland
- Study dates
- 21 Apr 2025to Aug 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age between 25 and 75 years.
- Sufficient understanding of the German language.
- Understanding the procedures and the risks that are associated with the study.
- Participants must be willing to adhere to the protocol and sign the consent form.
- Participants must be willing to refrain from taking illicit psychoactive substances during the study (not including cannabis).
- Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration.
- Women of childbearing potential must be willing to use effective birth-control throughout study participation
Who cannot join
- Chronic or acute medical condition, including a history of seizures.
- Body mass index 18-29.9 kg/m2
- Current or previous major psychiatric disorder (e.g. psychotic disorders, mania / hypomania, anxiety disorders).
- Psychotic or bipolar disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g., brain injury, dementia, or lesions of the brain.
- Hypertension (SBP>140/90 mmHg) or hypotension (SBP<85 mmHg)
- Psychedelic substance use (with the exception of cannabis) more than 20 times or any time within the previous two months
Show all 12Show fewer
- Pregnant or nursing women.
- Participation in another clinical trial (currently or within the last 30 days).
- Use of medications that may interfere with the effects of the study medications (any psychiatric medications and any medication with known to interact with the study substances).
- Tobacco smoking (>10 cigarettes/day).
- Consumption of alcoholic drinks (>15 drinks / week).
- Body weight < 45 kg.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Clinical Trial Unit
Basel, Canton of Basel-City, 4056
Friederike Holze, Doctor, +41613287735, friederike.holze@usb.ch
Matthias Liechti, Prof., +41613286868, matthias.liechti@usb.ch
About this study
Official title: Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)
Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Psilocybin is currently under investigation as potential treatment for various neuropsychiatric disorders. Psilocybin is also widely used for recreational purposes and as research tool in neuroscience. Besides its current clinical development, a clear characterization of the dose-response relationship of psilocybin is lacking. With the present study the investigators aim to close this knowledge gap by administering low (5mg) to high (40mg) single doses of psilocybin to healthy participants. Besides its agonism on 5-HT2A receptors, psilocin also binds to other receptors and inhibits serotonin transporters (SERT). To this data only few studies have investigated these effects and never at a high dose.
Read the detailed description
Psilocybin is widely used for recreational and spiritual purposes. Additionally Psilocybin is currently reused in experimental studies with healthy subjects and in studies investigating its effects on patients suffering from anxiety, depression, addiction personality disorders and other pathological conditions.
The present PDR-study will characterize the subjective effects of different doses of psilocybin using modern psychometric instruments, explore the relationship between the plasma-concentration of psilocybin and its subjective effects, and examine the contribution of the 5-HT2A receptor in the psilocybin-induced alterations of consciousness in a mechanistic study in healthy subjects.
Participants will recieve doses of 5, 10, 20, and 40 mg psilocybin, 40 mg of psilocybin with pretreatment of 40 mg ketanserin, and placebo (control for psilocybin). Placebo pretreatment (control for ketanserin) will be used for all psilocybin administrations without ketanserin. Administrations will be separated by at least 10 days and are in random and counter-balanced order.
- Conditions
- Healthy
- Being tested
- Ketanserin 40mg plus Psilocybin 40mg, 40mg Psilocybin, 20mg Psilocybin, 10mg Psilocybin, 5mg Psilocybin
- Keywords
- Hallucinogens, Physiological Effects of Drugs, Psychotropic Drugs, Serotonin Antagonists, Serotonin Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Serotonin Receptor Agonists, Psilocybin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ketanserin 40mg plus Psilocybin 40mgDrug
40mg Ketanserin oral will be administered followed by 40mg Psilocybin.
40mg PsilocybinDrug
Placebo oral followed by 40mg Psilocybin one hour later.
20mg PsilocybinDrug
Placebo oral followed by 20mg Psilocybin one hour later.
10mg PsilocybinDrug
Placebo oral followed by 10mg Psilocybin oral one hour later.
5mg PsilocybinDrug
Placebo oral followed by 5mg Psilocybin one hour later
PlaceboOther
Oral Placebo followed by oral Placebo one hour later
| Study group | Role | What they receive |
|---|---|---|
| 40mg Psilocybin plus 40mg Ketanserin | Experimental | 40mg Ketanserin oral followed by 40mg Psilocybin oral one hour later Receives: Drug: Ketanserin 40mg plus Psilocybin 40mg |
| 40mg Psilocybin | Experimental | 40mg Psilocybin oral Receives: Drug: 40mg Psilocybin |
| 20mg Psilocybin | Experimental | 20mg Psilocybin oral Receives: Drug: 20mg Psilocybin |
| 10mg Psilocybin | Experimental | 10mg Psilocybin oral Receives: Drug: 10mg Psilocybin |
| 5mg Psilocybin | Experimental | 5mg Psilocybin oral Receives: Drug: 5mg Psilocybin |
| Placebo | Placebo comparator | Placebo followed by Placebo Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
5 dimensions of altered state of consciousness (5D-ASC) total OAV score
Visual analog scale consisting of 94 items. Constructed of five scales and allows assessing mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. Scales will be presented as 100 mm long horizontal lines marked with vertical lines by the participant.
Measured: 10 hours after substance administration
Secondary outcomes (24)
Visual Analog Scales (VAS) good effect rating
VAS will be presented as 100 mm long horizontal lines marked with "not at all" on the left and "extremely" on the right. The following VAS items will be used: "any drug effect", "good drug effect", "bad drug effect", "drug high", "anxiety", "nausea", "feeling depressed", "alteration of vision", "alterations of hearing", "sounds seem to influence what I see", "alteration of sense of time", "the boundaries between myself and my surroundings seem to blur", "I gain insights into contexts that were previously were inscrutable to me", "talkative", "open", "trust" and "the context of my thought is personal/impersonal". Subjects will mark the scale with vertical lines.
Measured: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Adjective Mood Rating Scale AMRS
The adjective mood rating scale (AMRS or EWL60S) is a 60-item Likert scale that allows repeated assessment of mood in 6 dimensions: activation, inactivation, well-being, anxiety/depressed mood, extroversion and introversion, and emotional excitability.The AMRS consists of subscales measuring "activation", "positive mood", "extroversion", "introversion", "inactivation", and "emotional excitability.
Measured: One hour before as well as 3, 6, 10 and 24 hours after substance administration
States of consciousness questionnaire (SCQ)
This 100-item questionnaire is rated on a six-point scale. Forty-three items embedded into this questionnaire comprise the Mystical Experience Questionnaire (MEQ). which is sensitive to the effects of psilocybin. The 43 items provide scale scores for each of seven domains of mystical experiences: internal unity (pure awareness, a merging with ultimate reality), external unity (unity of all things, all things are alive, all is one), sense of sacredness (reverence, sacred), noetic quality (encounter with ultimate reality, more real than everyday reality), transcendence of time and space, deeply felt positive mood (joy, peace, love), paradoxicality/ineffability (claim of difficulty in describing the experience in words). The investigators will also derived the four scale scores of the newly validated revised 30-item MEQ: mystical, positive mood, transcendence of time and space, and ineffability.
Measured: 10 hours after substance administration
Phenomenological-Autobiographical-Existential Psychedelic Scale extended (PAE-PS-ext)
This questionnaire rates psychedelic experiences with a focus on phenomenological, autobiographical, and existential psychedelic experiences. The scale includes 12 main questions to be answered on a total of 78 sub-ordered visual rating scales (sub-ordered visual rating scales mostly only need to be answered when the answer to the main question is "yes"). The last major question with eight sub-ordered visual rating scales of the PAE-PS is on worldview/beliefs.
Measured: This questionnaire is administrated once before the first substance day (during screening), and then again 10h after substance administration on everx study visit..
Acute autonomic effects I (blood pressure)
Blood pressure (systolic and diastolic) will be measured with an automatic oscillometric device.
Measured: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Acute autonomic effects II (heart rate)
Heart rate will be measured with an automatic oscillometric device.
Measured: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Acute autonomic effects III (body temperature)
Body temperature will be measured with an ear thermometer.
Measured: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Effect moderation by personality traits I (NEO-FFI)
Personality traits are known to affect subjective responses to psychoactive substances and are assessed for explorative future analysis of pooled data. The NEO Five Factor Inventory (NEO-FFI) is a self-description questionnaire with 60 items for the measurement of the "big five": neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from "completely disagree" to "fully agree".
Measured: Screening
Effect moderation by personality traits II (FPI-R)
Personality traits are known to affect subjective responses to psychoactive substances and are assessed for explorative future analysis of pooled data. The Freiburger Personality Inventory (FPI-R) version comprises 138 items and covers 12 dimensions of personality: life satisfaction, social orientation, performance orientation, inhibition, excitability, aggressiveness, stress, physical complaints, health concerns, openness, as well as the secondary factors according to Eysenck's Extraversion and Emotionality (Neuroticism). It uses a 2-point scale ("true" and "not true").
Measured: Screening
Effect moderation by personality traits III (SPF)
Personality traits are known to affect subjective responses to psychoactive substances and are assessed for explorative future analysis of pooled data. The Saarbrücker Persönlichkeitsfragebogen (SPF) defines empathy as the "reactions of one individual to the observed experiences of another." It assesses 28-items on a 5-point Likert scale ranging from "Does not describe me well" to "Describes me very well". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.
Measured: Screening
Effect moderation by personality traits IV (HEXACO)
Personality traits are known to affect subjective responses to psychoactive substances and are assessed for explorative future analysis of pooled data. The HEXACO personality inventory is a six-dimensional model of human personality with 100 items.The six factors are: Honesty-Humility, Emotionality, Extraversion, Agreeableness, Conscientiousness and Openness to Experience.
Measured: Screening
Effect moderation by personality traits V (DSQ-40)
Personality traits are known to affect subjective responses to psychoactive substances and are assessed for explorative future analysis of pooled data. The Defense Style Questionnaire (DSQ-40) can provide scores for 20 individual defenses, and scores for the three factors "mature", "neurotic", and "immature". Each item is evaluated on a scale from 1 to 9, where "1" indicates "completely disagree" and "9" indicates "fully agree".
Measured: Screening
Psychological Insight Questionnaire (EBI+)
Assesses the degree of psychological insight caused by a psychedelic experience through 14-items to be answered on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely").
Measured: 10 hours after substance administration
Changes in the electrocardiogram (ECG)
Corrected QT time (QTc) will be measured twice on the study days (baseline and at peak drug effect) to examine possible drug-induced changes in the ECG as well as a safety measure (millisecond scale).
Measured: One hour before and 2 hours after substance administration.
Adverse effects (acute and subacute)
The 2011 revised Beschwerden-Liste (B-LR) consists of a 40-item list covering a wide variety of symptoms and complaints that are answered with a four-point intensity-scoring ranging from "not at all" to "strong".
Measured: One hour before, 10 and 24 hours after substance administration
Persisting effects of the psychedelic experiences (PEQ)
140 items are rated on a six-point scale and include attitudes about life (13 positive and 13 negative items), attitudes about self (11 positive and 11 negative items), mood changes (nine positive and nine negative items), behavioral changes (one positive and one negative item), spirituality (22 positive and 21 negative items). Three additional questions are included
Measured: End of study (EOS) visit during EOS interview
Cognitive Tasks
Cognitive assessment will be conducted using established tasks from the CANTAB battery. The tasks are administered in a computerized format.
Measured: 24 hours after substance administration
Peak Plasma concentration of Psilocybin and Metabolites (Cmax)
Maximal Plasma concentration of Psilocybin and Metabolites Cmax after substance administration. Calculated via blood samples.
Measured: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Time to cmax (Tmax)
Time until Psilocybin and Metabolites concentration peak in plasma after substance administration. Calculatet via blood samples after substance administration.
Measured: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Area under the concentration-time curve up to 24 h (AUC0-24)
Area under the plasma concentration versus time curve for psilocybin and metaboliteswill be calculated up to 24h using blood sampels colected during the study visits after substance administration.
Measured: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Elimination half life values (t1/2)
The elimination half life values of Psilocybin and metabolites will be calculated using blood samples collected during study visits after substance administration.
Measured: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Sleep variables of %REM
Sleep phases will be scored in every study session using an automated sleep stage classification algorithm of the SomnoArt® armband. The SomnoArt® armband will record, acceleration (3D accelerometer), and heart rate (red-infrared pulse oximeter) activity. Variables of %REM sleep is calculated as REM sleep duration divided by total sleep duration).
Measured: 14 hours after substance administration until the end of the study day
REM Latency
Sleep phases will be scored in every study session using an automated sleep stage classification algorithm of the SomnoArt® armband. The SomnoArt® armband will record, acceleration (3D accelerometer), and heart rate (red-infrared pulse oximeter) activity. REM Latency is calculated as duration of non-REM sleep before the first REM phase.
Measured: 14 hours after substance administration until the end of the study day
REM Efficiency
Sleep phases will be scored in every study session using an automated sleep stage classification algorithm of the SomnoArt® armband. The SomnoArt® armband will record, acceleration (3D accelerometer), and heart rate (red-infrared pulse oximeter) activity. REM Efficiency is calculated as REM sleep duration divided by the total REM episode duration
Measured: 14 hours after substance administration until the end of the study day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2025
- Study start21 Apr 2025
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- 6-period random order, placebo-controlled, double-blind cross-over study
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06796361
- Sponsor's protocol ID
- BASEC 2024-01503
- Other IDs
- BASEC 2024-01503
- Acronym
- PDR
- Status last verified
- May 2025
- First submitted
- 13 Jan 2025
- Last updated
- 28 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)
- ClinicalTrials.gov ID
- NCT06796361
- Acronym / sponsor ID
- PDR / BASEC 2024-01503
- Conditions
- Healthy
- Keywords
- Hallucinogens, Physiological Effects of Drugs, Psychotropic Drugs, Serotonin Antagonists, Serotonin Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Serotonin Receptor Agonists
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 21 Apr 2025 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 28 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Psilocybin is currently under investigation as potential treatment for various neuropsychiatric disorders. Psilocybin is also widely used for recreational purposes and as research tool in neuroscience. Besides its current clinical development, a clear characterization of the dose-response relationship of psilocybin is lacking. With the present study the investigators aim to close this knowledge gap by administering low (5mg) to high (40mg) single doses of psilocybin to healthy participants. Besides its agonism on 5-HT2A receptors, psilocin also binds to other receptors and inhibits serotonin transporters (SERT). To this data only few studies have investigated these effects and never at a high dose.
Detailed description
Psilocybin is widely used for recreational and spiritual purposes. Additionally Psilocybin is currently reused in experimental studies with healthy subjects and in studies investigating its effects on patients suffering from anxiety, depression, addiction personality disorders and other pathological conditions.
The present PDR-study will characterize the subjective effects of different doses of psilocybin using modern psychometric instruments, explore the relationship between the plasma-concentration of psilocybin and its subjective effects, and examine the contribution of the 5-HT2A receptor in the psilocybin-induced alterations of consciousness in a mechanistic study in healthy subjects.
Participants will recieve doses of 5, 10, 20, and 40 mg psilocybin, 40 mg of psilocybin with pretreatment of 40 mg ketanserin, and placebo (control for psilocybin). Placebo pretreatment (control for ketanserin) will be used for all psilocybin administrations without ketanserin. Administrations will be separated by at least 10 days and are in random and counter-balanced order.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 6
- Model description
- 6-period random order, placebo-controlled, double-blind cross-over study
| Arm | Type | Receives |
|---|---|---|
| 40mg Psilocybin plus 40mg Ketanserin | Experimental | Drug: Ketanserin 40mg plus Psilocybin 40mg40mg Ketanserin oral followed by 40mg Psilocybin oral one hour later |
| 40mg Psilocybin | Experimental | Drug: 40mg Psilocybin40mg Psilocybin oral |
| 20mg Psilocybin | Experimental | Drug: 20mg Psilocybin20mg Psilocybin oral |
| 10mg Psilocybin | Experimental | Drug: 10mg Psilocybin10mg Psilocybin oral |
| 5mg Psilocybin | Experimental | Drug: 5mg Psilocybin5mg Psilocybin oral |
| Placebo | Placebo comparator | Other: PlaceboPlacebo followed by Placebo |
Who may qualify
- Ages
- 25 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age between 25 and 75 years.
- Sufficient understanding of the German language.
- Understanding the procedures and the risks that are associated with the study.
- Participants must be willing to adhere to the protocol and sign the consent form.
- Participants must be willing to refrain from taking illicit psychoactive substances during the study (not including cannabis).
Key exclusion criteria (12 listed)
- Chronic or acute medical condition, including a history of seizures.
- Body mass index 18-29.9 kg/m2
- Current or previous major psychiatric disorder (e.g. psychotic disorders, mania / hypomania, anxiety disorders).
- Psychotic or bipolar disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g., brain injury, dementia, or lesions of the brain.
- Hypertension (SBP>140/90 mmHg) or hypotension (SBP<85 mmHg)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ketanserin 40mg plus Psilocybin 40mg40mg Ketanserin oral will be administered followed by 40mg Psilocybin. | Drug | 40mg Psilocybin plus 40mg Ketanserin |
| 40mg PsilocybinPlacebo oral followed by 40mg Psilocybin one hour later. | Drug | 40mg Psilocybin |
| 20mg PsilocybinPlacebo oral followed by 20mg Psilocybin one hour later. | Drug | 20mg Psilocybin |
| 10mg PsilocybinPlacebo oral followed by 10mg Psilocybin oral one hour later. | Drug | 10mg Psilocybin |
| 5mg PsilocybinPlacebo oral followed by 5mg Psilocybin one hour later | Drug | 5mg Psilocybin |
| PlaceboOral Placebo followed by oral Placebo one hour later | Other | Placebo |
Primary outcome
5 dimensions of altered state of consciousness (5D-ASC) total OAV score
Time frame: 10 hours after substance administration
Visual analog scale consisting of 94 items. Constructed of five scales and allows assessing mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. Scales will be presented as 100 mm long horizontal lines marked with vertical lines by the participant.
24 secondary outcomes
Visual Analog Scales (VAS) good effect rating
Time frame: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Adjective Mood Rating Scale AMRS
Time frame: One hour before as well as 3, 6, 10 and 24 hours after substance administration
States of consciousness questionnaire (SCQ)
Time frame: 10 hours after substance administration
Phenomenological-Autobiographical-Existential Psychedelic Scale extended (PAE-PS-ext)
Time frame: This questionnaire is administrated once before the first substance day (during screening), and then again 10h after substance administration on everx study visit..
Acute autonomic effects I (blood pressure)
Time frame: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Acute autonomic effects II (heart rate)
Time frame: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Acute autonomic effects III (body temperature)
Time frame: One hour before, right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Effect moderation by personality traits I (NEO-FFI)
Time frame: Screening
Effect moderation by personality traits II (FPI-R)
Time frame: Screening
Effect moderation by personality traits III (SPF)
Time frame: Screening
Effect moderation by personality traits IV (HEXACO)
Time frame: Screening
Effect moderation by personality traits V (DSQ-40)
Time frame: Screening
Psychological Insight Questionnaire (EBI+)
Time frame: 10 hours after substance administration
Changes in the electrocardiogram (ECG)
Time frame: One hour before and 2 hours after substance administration.
Adverse effects (acute and subacute)
Time frame: One hour before, 10 and 24 hours after substance administration
Persisting effects of the psychedelic experiences (PEQ)
Time frame: End of study (EOS) visit during EOS interview
Cognitive Tasks
Time frame: 24 hours after substance administration
Peak Plasma concentration of Psilocybin and Metabolites (Cmax)
Time frame: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Time to cmax (Tmax)
Time frame: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Area under the concentration-time curve up to 24 h (AUC0-24)
Time frame: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Elimination half life values (t1/2)
Time frame: Right after and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours after substance administration
Sleep variables of %REM
Time frame: 14 hours after substance administration until the end of the study day
REM Latency
Time frame: 14 hours after substance administration until the end of the study day
REM Efficiency
Time frame: 14 hours after substance administration until the end of the study day
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2025.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Ketanserin 40mg plus Psilocybin 40mg, 40mg Psilocybin and 20mg Psilocybin in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
5 dimensions of altered state of consciousness (5D-ASC) total OAV score (time frame: 10 hours after substance administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2025.